Date:2/22/2010

reatments comprise an approximately $13 billion market.  Enbrel, a leading rheumatoid arthritis treatment sold by Amgen and Wyeth, reported US sales in 2007 of about $3.2 billion.  Enbrel is a soluble recombinant protein of a human TNF-alpha receptor linked to human IgG Fc.  In some cases, human or humanized monoclonal antibodies specific against TNF-alpha have also been used for therapy in rheumatoid arthritis.  These therapies remove or inactivate TNF-alpha, a natural human cytokine required in many immune functions for normal defenses.  

CEL-SCI's rheumatoid arthritis vaccine CEL-2000 was discovered as part of work with the Company's ongoing research and development activities with its L.E.A.P.S.™ (Ligand Epitope Antigen Presentation System) technology.  L.E.A.P.S. is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

The concept behind the L.E.A.P.S. technology is to directly mimic cell-cell interactions and activate immune cells with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to a immune-cell binding ligand (ICBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending
'/>"/>

SOURCE CEL-SCI Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. CEL-SCI Corporation Reports First Quarter 2010 Financial Results
3. CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
4. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
5. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
6. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
9. CEL-SCI Expands H1N1 Flu Virus Work
10. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
11. CEL-SCI Posts New Corporate Presentation to Website